{"data":[{"accessionNo":"0000093751-26-000400","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001070494","issuerName":"ACADIA PHARMACEUTICALS INC","ticker":"ACAD","cusip":"004225108","securityClass":"COMMON STOCK","eventDate":"2026-06-30","reportingPerson":"STATE STREET CORPORATION","reportingCik":null,"personType":"HC","sharesOwned":9076212,"percentOfClass":5.3,"filedAt":"2026-08-07","canonicalUrl":"https://xoomar.com/markets/stocks/acad"},{"accessionNo":"0002100121-26-000077","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001070494","issuerName":"ACADIA Pharmaceuticals Inc","ticker":"ACAD","cusip":"004225108","securityClass":"Common Stock","eventDate":"2026-03-31","reportingPerson":"Vanguard Portfolio Management","reportingCik":null,"personType":"IA","sharesOwned":8781007,"percentOfClass":5.15,"filedAt":"2026-04-28","canonicalUrl":"https://xoomar.com/markets/stocks/acad"},{"accessionNo":"0000102909-26-000519","formType":"SCHEDULE 13G/A","amendmentNo":9,"issuerCik":"0001070494","issuerName":"ACADIA Pharmaceuticals Inc","ticker":"ACAD","cusip":"004225108","securityClass":"Common Stock","eventDate":"2026-03-13","reportingPerson":"The Vanguard Group","reportingCik":null,"personType":"IA","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-03-26","canonicalUrl":"https://xoomar.com/markets/stocks/acad"},{"accessionNo":"0001104659-26-020778","formType":"SCHEDULE 13D/A","amendmentNo":17,"issuerCik":"0001070494","issuerName":"ACADIA Pharmaceuticals Inc.","ticker":"ACAD","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2026-02-24","reportingPerson":"Julian C. Baker","reportingCik":"0001087939","personType":"IN,HC","sharesOwned":43294373,"percentOfClass":25.4,"filedAt":"2026-02-26","canonicalUrl":"https://xoomar.com/markets/stocks/acad"},{"accessionNo":"0001104659-26-020778","formType":"SCHEDULE 13D/A","amendmentNo":17,"issuerCik":"0001070494","issuerName":"ACADIA Pharmaceuticals Inc.","ticker":"ACAD","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2026-02-24","reportingPerson":"Felix J. Baker","reportingCik":"0001087940","personType":"IN,HC","sharesOwned":43294373,"percentOfClass":25.4,"filedAt":"2026-02-26","canonicalUrl":"https://xoomar.com/markets/stocks/acad"},{"accessionNo":"0001104659-26-020778","formType":"SCHEDULE 13D/A","amendmentNo":17,"issuerCik":"0001070494","issuerName":"ACADIA Pharmaceuticals Inc.","ticker":"ACAD","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2026-02-24","reportingPerson":"Baker Bros. Advisors LP","reportingCik":"0001263508","personType":"IA,PN","sharesOwned":43151054,"percentOfClass":25.3,"filedAt":"2026-02-26","canonicalUrl":"https://xoomar.com/markets/stocks/acad"},{"accessionNo":"0001104659-26-020778","formType":"SCHEDULE 13D/A","amendmentNo":17,"issuerCik":"0001070494","issuerName":"ACADIA Pharmaceuticals Inc.","ticker":"ACAD","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2026-02-24","reportingPerson":"Baker Bros. Advisors (GP) LLC","reportingCik":"0001580575","personType":"HC,OO","sharesOwned":43151054,"percentOfClass":25.3,"filedAt":"2026-02-26","canonicalUrl":"https://xoomar.com/markets/stocks/acad"},{"accessionNo":"0001104659-26-020778","formType":"SCHEDULE 13D/A","amendmentNo":17,"issuerCik":"0001070494","issuerName":"ACADIA Pharmaceuticals Inc.","ticker":"ACAD","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2026-02-24","reportingPerson":"FBB3 LLC","reportingCik":"0001625395","personType":"OO","sharesOwned":40443,"percentOfClass":0.02,"filedAt":"2026-02-26","canonicalUrl":"https://xoomar.com/markets/stocks/acad"},{"accessionNo":"0001493215-25-000033","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001070494","issuerName":"ACADIA PHARMACEUTICALS INC.","ticker":"ACAD","cusip":null,"securityClass":"Common Stock, $0.0001 par value","eventDate":"2025-09-30","reportingPerson":"Roderick Wong","reportingCik":null,"personType":"HC,IN","sharesOwned":7144524,"percentOfClass":4.2,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/acad"},{"accessionNo":"0001493215-25-000033","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001070494","issuerName":"ACADIA PHARMACEUTICALS INC.","ticker":"ACAD","cusip":null,"securityClass":"Common Stock, $0.0001 par value","eventDate":"2025-09-30","reportingPerson":"RTW Investments, LP","reportingCik":null,"personType":"IA,PN","sharesOwned":7144524,"percentOfClass":4.2,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/acad"}],"updatedAt":"2026-11-03T18:37:59.567Z","source":"xoomar.com","docs":"https://xoomar.com/markets/api","license":"https://xoomar.com/terms","attribution":"Credit XOOMAR with a link to the dataset page on xoomar.com when you republish this data","canonicalUrl":"https://xoomar.com/markets/stocks/acad","meta":{"source":"SEC","sourceAttribution":"Schedule 13D and 13G data: SEC.","notice":"10 requests a minute without a key, 30 with a free key. Get a free key at https://xoomar.com/signup?utm_source=api, register your app at https://xoomar.com/developers/register?utm_source=api, and credit the data as \"Data: XOOMAR\" together with the sourceAttribution line."}}